• Immunome released detailed Phase 3 RINGSIDE results for varegacestat in progressing desmoid tumors, presented May 30, 2026 at ASCO.
• The study showed a clear benefit on delaying disease worsening versus placebo, with responses that supported tumor shrinkage.
• Patients also reported a rapid, clinically meaningful reduction in pain versus placebo.
• Safety was described as manageable for the drug class, though side effects drove frequent dose reductions and some treatment stops.
• An FDA NDA was filed in April 2026, positioning varegacestat as a potential new standard option if cleared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260530890115) on May 30, 2026, and is solely responsible for the information contained therein.